Private Equity Articles

A Dead Simple Solution to Save Your Retirement

Wayne and I opened up a big can of worms in our articles last week: The retirement crisis. As we explained, the average 50-year-old today has less than $50,000 saved for retirement… And 45% of Americans have nothing saved for retirement at all — zero. But now that we’ve recognized…

Read More

Tags: Private Equity Retirement

Your 2017 Battle Plan

This is the last time you’ll hear from me in 2016. By the time I write to you again next week, it’ll be a brand new year. And I want to help you begin preparing for it right now... That’s because 2017 promises to be a big year for investors.…

Read More

Tags: Private Equity Asset Allocation

2016 Forecast: Growth Sectors

Right around this time last year, we issued our forecasts for 2015— We offered you our perspective on which sectors and investment themes would be important for the coming year. Today, we’ll review our predictions and see how they panned out... And then we’ll tell you where you should focus…

Read More

Tags: Private Equity Pot Stocks

Tech Glitch Hands You Double-Digit Gains

First, a warning: This is going to be a little different than usual... You see, nine times out of ten, when Crowdability writes about technology, we focus on all the things that could go right— From how technology can help solve major problems around the world, to how it can…

Read More

Tags: Private Equity

The "Little Blue Pill" for Your Portfolio

Once upon a time, there was a little blue pill. Originally, it was designed to treat heart disease... But during its initial trials, doctors discovered an intriguing "side effect." Eventually, this side effect became so popular that sales of the little pill reached into the billions of dollars. If you…

Read More

Tags: Pre-IPO Private Equity Sharespost GSVC

Our Favorite Biotech Trade

Over the past 12 months, biotech’s been booming: In fact, the NASDAQ Biotechnology Index (NBI) has risen by more than 46%. IPOs have played a big part in that rise... For example, Ultragenyx Pharmaceutical (NASDAQ: RARE), debuted at $21 and now sits at over $60 per share. That’s a 300% return…

Read More

Tags: Biotech IPO Pre-IPO Private Equity

2015 Forecast: Growth Sectors

Matt and I have a year-end tradition: On the Sunday after Thanksgiving, while our NYC office is still quiet, we sit in the lounge chairs by our big, south-facing windows... As we gaze over lower Manhattan towards the Statue of Liberty, we ask ourselves an important question about the year…

Read More

Tags: Private Equity

Cyber Security: The Next Tech Megatrend

According to a high-ranking government official, we’re currently witnessing “the greatest transfer of wealth in history.” But this transfer isn’t coming from the stock or bond market, or any other market you can think of. It has a more shocking source: Cybercrime Chaos… And Opportunity Cybercrime costs U.S. corporations an…

Read More

Tags: Equity Crowdfunding Crowdfunding Facebook Venture Capital Early-stage Start-ups Private Equity Cyber Security Cyber Attacks Security